| abstract |
The present invention provides for the treatment of primary headache disorders, particularly migraine, using antagonists of the EP 4 receptor for prostaglandin E2. Particular EP 4 receptor antagonists include azole compounds of formula (I): n n n wherein R 1 is a group such as lower alkyl substituted with carboxy; R 2 is hydrogen or lower alkyl, R 3 and R 4 are aryl optionally substituted with halogen, n n n in which —A 1 — is a single bond or lower alkylene, n n n is a cyclo group, n —A 3 — is a single bond or lower alkylene, and X is O, NH or S; n or a salt or its solvate thereof. |